Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients, of age 18 - 54 years~* Patients diagnosed with stage 1 or stage 2 essential hypertension~* Normal physical examination findings and electrocardiogram (ECG) results or abnormal findings judged by the Investigator to be not clinically significant~Exclusion Criteria:~* Secondary hypertension or severe hypertension~* History of Type 1 diabetes mellitus~* A medical contraindication to discontinuing a current antihypertensive therapy~* Clinically significant respiratory disease that prohibit use of a beta blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
- 2 (Type: PLACEBO_COMPARATOR): Dose-matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).